Pipeline

Substantial pipeline and partnering
assets and opportunities


Our AMP platform, originally developed at MIT, has broad potential across cancers, infectious diseases and other disease indications to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. Among our development candidates, we intend to internally advance ELI-002 for KRAS-driven cancers, ELI-003 for cancers involving an ALK mutation, ELI-011 for hematological cancers, and ELI-004, our universal adjuvant utilized in each pipeline program. We have conducted initial assessments related to the potential use of the AMP platform to treat additional diseases, including COVID-19, and these indications may be well-suited for treatment using an AMP construct, and we intend to advance them through out-licensing, co-development or other partnership arrangements. Our most advanced development initiatives, their current stage of development and the next anticipated major milestone for each program are presented in the chart below.

Elicio pipeline October 1